4'-{1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methyl-phenyl]-propyl}-2'-methyl-biphenyl-3-carboxylic acid | 917022-64-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4'-{1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methyl-phenyl]-propyl}-2'-methyl-biphenyl-3-carboxylic acid
• 英文别名: 3-[4-[3-[4-[(E)-3-ethyl-3-hydroxypent-1-enyl]-3-methylphenyl]pentan-3-yl]-2-methylphenyl]benzoic acid
• CAS: 917022-64-1
• 化学式: C₃₃H₄₀O₃
• 分子量: 484.679
• InChiKey: NAGBPQHVQGUJDG-VHEBQXMUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.1
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-[1-ethyl-1-(4-ethynyl-3-methylphenyl)-propyl]-2-methylphenol 在 四(三苯基膦)钯 吡啶 、 lithium aluminium tetrahydride 、 正丁基锂 、 potassium carbonate 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.08h， 生成 4'-{1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methyl-phenyl]-propyl}-2'-methyl-biphenyl-3-carboxylic acid
  参考文献：
  名称：

  VITAMIN D-LIKE COMPOUND

  摘要：

  本发明提供了一种由下列通式（I）表示的化合物： 或其药用的可接受盐，包含该化合物的药物组合物等。该化合物或其药用的可接受盐，包含该化合物的药物组合物等，用作治疗良性前列腺增生、癌症、骨质疏松症、银屑病、继发性甲状旁腺功能亢进、慢性肾小球肾炎、狼疮性肾炎和/或糖尿病性肾病等的药物等。

  公开号：

  EP1894911A1

文献信息

• VITAMIN-D-LIKE COMPOUNDS
  申请人：TAKAHASHI TADAKATSU

  公开号：US20110060146A1

  公开（公告）日：2011-03-10

  The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.

  本发明提供了以下一般式(I)所代表的化合物或其药学上可接受的盐，含有这种化合物的制药组合物等。该化合物或其药学上可接受的盐，含有这种化合物的制药组合物等可用作治疗良性前列腺增生、癌症、骨质疏松症、银屑病、继发性甲状旁腺功能亢进症、慢性肾小球肾炎、狼疮性肾炎和/或糖尿病肾病等药物或类似物。
• Vitamin D-like compound
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US07935688B2

  公开（公告）日：2011-05-03

  The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.

  本发明提供了一种由以下通式（I）表示的化合物或其药学上可接受的盐，含有该化合物的药物组合物等。该化合物或其药学上可接受的盐，含有该化合物的药物组合物等可用作治疗良性前列腺增生、癌症、骨质疏松症、银屑病、继发性甲状旁腺功能亢进症、慢性肾小球肾炎、狼疮性肾炎和/或糖尿病肾病等疾病的药物或类似物。
• A series of nonsecosteroidal vitamin D receptor agonists for osteoporosis therapy
  作者：Hirotaka Kashiwagi、Yoshiyuki Ono、Masateru Ohta、Susumu Itoh、Fumihiko Ichikawa、Suguru Harada、Satoshi Takeda、Nobuo Sekiguchi、Masaki Ishigai、Tadakatsu Takahashi

  DOI：10.1016/j.bmc.2013.01.042

  日期：2013.4

  In an extension of our study on gamma hydroxy carboxylic acid analogs, we explored a series of nonsecosteroidal vitamin D receptor (VDR) agonists in which 1,3-diol of 1,25(OH)(2)D-3 had been replaced by aryl acetic acid. These analogs showed very potent activity in vitro compared with 1,25(OH)(2)D-3. An X-ray analysis of 8d showed that the inserted phenyl ring well mimicked the folded methylene linker of the gamma hydroxy carboxylic acid moiety but the carboxylic acid of 8d interacted with VDR in a different manner from gamma hydroxy carboxylic acids. Through our in vivo screening in an osteoporosis rat model using immature rats, we identified a potent active vitamin D-3 analog, compound 7e. In mature rats of the same model, compound 7e also showed good PK profiling and excellent ability to prevent bone mineral density loss without severe hypercalcemia. Our nonsecosteroidal VDR agonist 7e (CH5036249) could be a possible new drug candidate for treating osteoporosis in human. (C) 2013 Elsevier Ltd. All rights reserved.
• US7935688B2
  申请人：——

  公开号：US7935688B2

  公开（公告）日：2011-05-03
• VITAMIN D-LIKE COMPOUND
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1894911A1

  公开（公告）日：2008-03-05

  The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.

  本发明提供了一种由下列通式（I）表示的化合物： 或其药用的可接受盐，包含该化合物的药物组合物等。该化合物或其药用的可接受盐，包含该化合物的药物组合物等，用作治疗良性前列腺增生、癌症、骨质疏松症、银屑病、继发性甲状旁腺功能亢进、慢性肾小球肾炎、狼疮性肾炎和/或糖尿病性肾病等的药物等。